TABLE 4.

Reports about thromboembolism in gastric endoscopic submucosal dissection (ESD)

Author, year	Study population	No. of cases	No. of events (rate)	Type of thromboembolic event	Status of AT agents in cases with event
Lim et al., 2012 80	All patients	1503	1 (0.07%)	Cerebral infarction	Discontinuation of antiplatelet agents
Takeuchi et al., 2013 94	All patients	833	1 (0.12%)	Cerebral infarction	Discontinuation of AT agent (detail unclear)
Yoshio et al., 2013 93	All patients	1250	1 (0.08%)	Cerebral infarction	Discontinuation of aspirin, P2Y12 receptor antagonist, and cilostazol with heparin bridging
Sanomura et al., 2014 92	Patients on aspirin	78	4 (5.1%)	2, cerebral infarction; 2, myocardial infarction	All, discontinuation of aspirin
Igarashi et al., 2017 91	Patients on AT agents	367	4 (1.1%)	2, cerebral infarction; 1, TIA; 1, angina pectoris	All, discontinuation of antiplatelet agents
Shiroma et al., 2021 90	All patients	10,320	3 (0.03%)	2, cerebral infarction; 1, TIA	1, discontinuation of warfarin; 1, discontinuation of warfarin with heparin bridging; 1, continuation of DOAC with heparin bridging

Abbreviations: AT, antithrombotic; DOAC, direct oral anticoagulant; TIA, transient ischemic attack.